April 4th 2025
The study found dupilumab-treated patients had the highest probability of remaining infection-free over 52 weeks.
Clinical Consultations™: Optimizing Treatment Outcomes for Patients with Generalized Pustular Psoriasis
View More
Revolutionizing Atopic Dermatitis (RAD) Conference 2025
June 6-7, 2025
Register Now!
Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient
July 26, 2025
Register Now!
Advances in™ Atopic Dermatitis: Addressing Unmet Needs in Patients With Skin of Color
View More
Clinical Consultations™: Guiding Patients with Genital Psoriasis Toward Relief Through a Multidisciplinary Approach
View More
Patient, Provider & Caregiver Connection™: Understanding the Patient Journey to Provide Personalized Care for Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Practice Techniques to Optimize Diagnosis and Treatment Strategies in Generalized Pustular Psoriasis
View More
Cases and Conversations™: Applying Best Practices to Prevent Shingles in Your Practice
View More
‘REEL’ Time Patient Counseling™: Fostering Effective Conversations in Practice to Create a Visible Impact for Patients Living with Genital Psoriasis
View More
Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis
View More
Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?
View More
Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management
View More
Burst CME: Targeted Therapy for Optimal Psoriasis Management
View More
Moisturizers offer easy, low-cost option for kids with atopic dermatitis
January 16th 2020Anneke Andriessen, Ph.D. discusses research that suggests controlling symptoms with moisturizers can be an important - and inexpensive - prevention and treatment tactic for pediatric patients with atopic dermatitis.
Tralokinumab meets endpoints for all phase 3 studies
December 16th 2019LEO Pharma has recently announced that all three phase 3 studies examining the safety and efficacy of the atopic dermatitis investigational drug tralokinumab met all of its primary and secondary endpoints, leading way to the company now seeking marketing authorization for the drug.
Tape strips may replace biopsies in pediatric atopic dermatitis
December 13th 2019Biopsies are the gold standard approach for obtaining skin samples to test for biomarkers in atopic dermatitis, but tape strips may offer a far less invasive alternative for young children with the disease, research suggests.
High risk of conjunctivitis in atopic dermatitis patients
December 12th 2019Dermatologists should look for signs of conjunctivitis in their atopic dermatitis patients and learn how to manage the condition because this patients population may have an increased risk of experiencing conjunctivitis, particularly allergic conjunctivitis, according to a recent study.
Fast Track designation granted to lebrikizumab for atopic dermatitis
December 11th 2019The U.S. FDA has granted Dermira with a Fast Track designation for its atopic dermatitis drug lebrikizumab following the start of phase 3 clinical trials to examine the efficacy, tolerability and safety of the drug.
Itch may require different treatment approaches
November 19th 2019Understanding the pattern of pruritus in various autoimmune connective tissue diseases may help physicians identify different etiologies that will inform different treatment targets to alleviate the symptom, according to researchers who examined pruritus relative to disease.
Inflammation-associated itching perceived as more intense
November 19th 2019A recent study showing that patients perceive inflammation-associated itch as more intense and qualitatively different than itch without inflammation suggests that dermatologists target inflammation in conditions such as atopic dermatitis.
Lifestyle recommendations challenging to identify, but may help
November 18th 2019Lifestyle recommendations are an interesting and complex aspect of eczema care. There are many things that can impact eczema severity and are in a patient's control to a certain extent. However, offering suggestions that can actually help patients can be challenging, one expert says.
Atopic dermatitis in elderly common, hard to treat
November 11th 2019Adults 60 years and older tend to have a distinct atopic dermatitis presentation and important comorbidities, but dermatologists treating these patients find lacking evidence on how to diagnose and best treat atopic dermatitis in the elderly, according to a recent review.